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Background. Co-morbid major depression occurs in approximately 10% of people suffering from a chronic medical
condition such as cancer. Systematic integrated management that includes both identiﬁcation and treatment has been
advocated. However, we lack information on the cost-effectiveness of this combined approach, as published evaluations
have focused solely on the systematic (collaborative care) treatment stage. We therefore aimed to use the best available
evidence to estimate the cost-effectiveness of systematic integrated management (both identiﬁcation and treatment)
compared with usual practice, for patients attending specialist cancer clinics.
Method. We conducted a cost-effectiveness analysis using a decision analytic model structured to reﬂect both the
identiﬁcation and treatment processes. Evidence was taken from reviews of relevant clinical trials and from observational
studies, together with data from a large depression screening service. Sensitivity and scenario analyses were undertaken
to determine the effects of variations in depression incidence rates, time horizons and patient characteristics.
Results. Systematic integrated depression management generated more costs than usual practice, but also more quality-
adjusted life years (QALYs). The incremental cost-effectiveness ratio (ICER) was £11765 per QALY. This ﬁnding was
robust to tests of uncertainty and variation in key model parameters.
Conclusions. Systematic integrated management of co-morbid major depression in cancer patients is likely to be cost-
effective at widely accepted threshold values and may be a better way of generating QALYs for cancer patients than
some existing medical and surgical treatments. It could usefully be applied to other chronic medical conditions.
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Introduction
A substantial proportion of patients with chronic
medical conditions report depressive symptoms and
approximately 10% meet criteria for a diagnosis of
major depression (Moussavi et al. 2007). This co-
morbid major depression severely impairs patients’
quality of life, reduces their compliance with medical
treatments and increases the costs of medical care
(Katon & Ciechanowski, 2002).
The importance of co-morbid depression should
make its effectivemanagement apriority; unfortunately,
management is often inadequate in practice, with
shortcomings in both identiﬁcation and treatment
(Greenberg, 2004; Cepoiu et al. 2008; Mitchell et al.
2009; Coventry et al. 2011; Fann et al. 2012). Depression
is frequently unidentiﬁed in the medical consultation
because the relevant symptoms are normalized or are
simply not discussed, in part because patient and clini-
cian focus on the management of the medical condition
(Cape & McCulloch, 1999; Nutting et al. 2000). When
identiﬁed, depression is often inadequately treated
with insufﬁcient patient education, failure to prescribe
minimally effective doses of antidepressant drugs,
inadequate provision of psychological treatment and
failure to monitor outcomes and adjust treatment
accordingly (Fann et al. 2012).
New approaches have been developed to address
these shortcomings in care. Systematic identiﬁcation
of cases by screening medical clinics is an important
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ﬁrst step (NICE, 2009b; U.S. Preventive Services Task
Force, 2009). However, it is ineffective in improving
patient outcomes if used alone (Gilbody et al. 2001,
2006). Case identiﬁcation therefore needs to be linked
with systematic treatment integrated with medical care
that typically includes: a multi-disciplinary approach,
a structured management plan, a proactive approach
to patient follow-up and enhanced interprofessional
communication (Gunn et al. 2006). This approach has
been called ‘collaborative care’ (Katon, 2012).
Although the systematic treatment for cases identiﬁed
by screening has been found to be cost-effective for
depression co-morbid with some chronic medical con-
ditions, including cancer, heart disease and diabetes,
the cost-effectiveness evaluations have not adequately
addressed the cost-effectiveness of the screening com-
ponent. Hence we lack data on the cost-effectiveness
of systematic depression management comprising
both systematic identiﬁcation and treatment.
Two of the authors of this paper (J.W. and M.S.) have
developed a systematic approach to the identiﬁcation
and treatment of major depression for cancer out-
patients that combines systematic case identiﬁcation
by a two-stage screening system in cancer clinics with
a systematic collaborative care type treatment inte-
grated with cancer care, known as ‘Depression Care
for People with Cancer’ (DCPC; Walker & Sharpe,
2009). The treatment was evaluated in the Symptom
Management Research Trials in Oncology-1 (SmaRT
Oncology-1) and found to be effective (Strong et al.
2008). However, as with other similar studies, the
cost-effectiveness of the whole depression management
system, including both systematic screening and sys-
tematic treatment, has not been determined.
In the current study we aimed to achieve the best
estimate of the cost-effectiveness of systematic inte-
grated depression management, including both sys-
tematic case identiﬁcation and systematic treatment,
when compared with usual practice for patients with
major depression attending specialist cancer services
by using multiple sources of data to supplement the
data from SMaRT Oncology-1.
Method
Design
We conducted a cost-effectiveness analysis, using a
decision analytic model and taking the perspective of
a budget-constrained health-care system, to compare
systematic depression identiﬁcation and treatment (as
an addition to usual practice) with usual practice
alone. We focused on major depression because this
denotes a severity and persistence of depressive symp-
toms that is generally considered to require treatment.
We used data from our screening system, individual
patient data from our clinical trial of DCPC and data
from other published reports (Table 1 contains a full
list of data sources). Outcomes were quality-adjusted
life years (QALYs) achieved and costs incurred to the
health-care system.
Population
Our study sample comprised adult patients diagnosed
with cancer (any type) attending specialist cancer out-
patient services at any stage of treatment or follow-up,
with an estimated life expectancy of 51 year. The
analysis was limited to adult patients with relatively
good cancer prognosis because we considered that
younger patients and those near the end of life require
different types of treatment for depression.
Depression identiﬁcation and treatment (Fig. 1)
Usual practice
(1) Identiﬁcation of major depression by the patient’s
primary care physician (PCP) using their clinical
skills (assisted by a standardized screening ques-
tionnaire if necessary).
(2) Treatment of depression based on the PCP’s clini-
cal judgement; any combination of ‘watchful wait-
ing’, prescription of antidepressant medication and
referral for psychological treatment.
Systematic identiﬁcation and treatment
(1) Identiﬁcation of major depression using a two-stage
screening system in specialist cancer clinics. In stage
1, screening staff assist patients to complete the
Hospital Anxiety and Depression Scale (HADS)
while waiting for their clinic appointment
(Zigmond & Snaith, 1983). In stage 2, patients
whose total HADS score is 515 are telephoned at
home, soon after their clinic appointment, and a
brief diagnostic interview for major depression is
administered (First et al. 1996). (A HADS total
score of515 has been found to be optimal for iden-
tifying cancer patients at risk of major depression;
Walker et al. 2007.) At the end of the call, patients
with major depression are advised to see their PCP
or oncology clinician, both of whom receive a report
from the screening service informing them of the
diagnosis of major depression.
(2) Treatment of major depression using DCPC
(Walker & Sharpe, 2009). We have described DCPC
in detail elsewhere (Walker & Sharpe, 2009). In
summary, DCPC is a multicomponent, systematic,
team-delivered treatment programme integrated
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with the patient’s cancer care. The treatment team
comprises specially trained cancer nurses,
consultation-liaison psychiatrists and the patient’s
PCP. The nurses provide education about de-
pression and its treatment, deliver brief evidence-
basedpsychological interventions (problem-solving
therapy, behavioural activation) and monitor
the patient’s progress using the Patient Health
Questionnaire nine-item depression scale (PHQ-9;
Kroenke et al. 2001; Hopko et al. 2003; Mynor-
Wallis, 2005). The psychiatrists supervise treatment
with the aimof achievingandmaintaining treatment
targets, advise PCPs about prescribing antidepress-
ant medication and provide direct consultations to
Table 1. Parameter estimates used in the model
Parameter
Mean
value
Distribution
for PSA Source
Epidemiology of depression in cancer patients
Prevalence of major depression 0.078 Beta Sharpe et al. 2004
Incidence of major depression 0.021 Fixed NICE, 2009a
HRQoL scores [anchored on 0 (dead) and 1 (good health)]
Not depressed 0.86 Beta Revicki & Wood, 1998
Depressed (identiﬁed or unidentiﬁed, initial or relapse) 0.447 Beta Strong et al. 2008
Remission 0.685 Beta Strong et al. 2008
Usual care: identiﬁcation
Sensitivity of PCP interview 0.501 Fixed Mitchell et al. 2009
Speciﬁcity of PCP interview 0.813 Fixed Mitchell et al. 2009
Cost of PCP interview (one consultation) (£) 36 Fixed Curtis, 2011
Usual care: treatment
Monthly probability of remission 0.1305 Beta Strong et al. 2008
Monthly probability of relapse during treatment 0.0246 Beta Strong et al. 2008
Monthly probability of relapse when treatment complete 0.0776 Beta Geddes et al. 2003;
Strong et al. 2008
Monthly cost of PCP treatment (£) 28.71 Gamma Strong et al. 2008
Systematic management: identiﬁcation
Sensitivity of HADS cut-off 15 0.8667 Beta Walker et al. 2007
Speciﬁcity of HADS cut-off 15 0.852 Beta Walker et al. 2007
Probability of completing HADS 0.896 Beta SMS data
Cost of HADS (5min SMS assistant time) (£) 2 Fixed SMS data; Curtis, 2011
Probability of completing structured diagnostic
interview for depression
0.851 Beta SMS data
Cost of structured diagnostic interview for depression
(15min SMS assistant time for depressed patients,
5 min for patients without depression)+6min
psychiatrist supervision time per interview (£)
10.35 Fixed SMS data; Curtis, 2011
Systematic management: treatment
Monthly probability of remission 0.1879 Beta Strong et al. 2008
Monthly probability of relapse during treatment 0.0246 Beta Strong et al. 2008
Monthly probability of relapse when treatment complete 0.0776 Beta Geddes et al. 2003;
Strong et al. 2008
Initial cost of DCPC treatment (£) 261.65 Gamma Strong et al. 2008
Monthly cost of DCPC treatment (£) 40.91 Gamma Strong et al. 2008
No treatment (unidentiﬁed depression)
Monthly probability of remission 0.1020 Beta Strong et al. 2008;
Arroll et al. 2009
Monthly probability of relapse 0.0776 Beta Geddes et al. 2003;
Strong et al. 2008
Monthly cost (£) 20.35 Gamma Strong et al. 2008
PSA, Probabilistic sensitivity analysis; HRQoL health-related quality of life; PCP, primary care physician; HADS, Hospital
Anxiety and Depression Scale; SMS, Symptom Monitoring Service; DCPC, Depression Care for People with Cancer.
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patients who are not progressing. The initial treat-
ment phase comprises a maximum of 10 sessions
with the nurse, given over 4 months. The patient’s
PHQ-9 scores are then monitored monthly by tele-
phone and additional sessions are provided for
patients who do not meet the treatment targets.
Costs and outcomes
Costs, from the perspective of the UK National Health
Service (NHS) and Personal Social Services (PSS), were
expressed in pounds sterling at 2010 prices. Outcomes
were measured in QALYs, a generic measure that
combines any effect of interventions on both life
expectancy and health-related quality of life (HRQoL;
Drummond et al. 2005). QALYs are the most widely
used generic measure of outcome in health care.
Model structure
We constructed a model consisting of two linked
parts: the ﬁrst represented the process of identiﬁcation
of depressed patients from the cancer population;
and the second captured patient outcomes and costs
over a time horizon of 5 years including the effects of
depression treatments. The model structure was
based on reviews of other models in the literature
and discussions with clinicians (Valenstein et al.
2001; Sobocki et al. 2006; Paulden et al. 2009;
NCCMH, 2010). These models are shown in online
Supplementary Figs S1 and S2.
In the ﬁrst part of the model, patients entered the
identiﬁcation processes as either ‘depressed’ or ‘not
depressed’. They emerged from these in one of three
states: ‘depressed-identiﬁed’, ‘depressed-not ident-
iﬁed’ and ‘not depressed’. The proportion of patients
in each of these states was dependent on the preva-
lence of depression in people with cancer and on the
performance and uptake of the identiﬁcation systems.
Patients then entered the second part of the model
in one of these three states. They could remain in
these states or move to other states, each of which
had an associated HRQoL score and cost. For example,
depressed patients could remain depressed or move
into remission. The probabilities of making transitions
between states differed by treatment, reﬂecting differ-
ential effectiveness. It was assumed that patients with
unidentiﬁed depression did not receive any treatment.
Patients incorrectly diagnosed with depression, which
was assumed to only be possible through identiﬁcation
within usual practice because the diagnostic interview
used in the second stage of systematic screening was
a ‘gold standard’ instrument and therefore assumed
to have 100% speciﬁcity (i.e. no false positives), were
included in the ‘not depressed’ state but were assumed
to receive treatment and therefore incur costs but
derive no beneﬁts.
Data sources
Identiﬁcation
We obtained parameter estimates for identiﬁcation
of depression from the screening system and from
published literature. Table 1 contains a list of data
sources and parameter estimates. We estimated the
Fig. 1. Components of depression management. HADS, Hospital Anxiety and Depression Scale; DCPC, Depression Care for
People with Cancer; PCP, primary care physician.
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number of PCP consultations using published UK
data, which indicated that patients with chronic
medical conditions attended an average of nine PCP
appointments per year (Department of Health,
2011b). We assumed that the PCP assessed patients
for depression at each visit; the sensitivity and speciﬁ-
city of this assessment in diagnosing major depression
was estimated from a meta-analysis (Mitchell et al.
2009). We assumed that the resource use involved in
making a diagnosis of depression in usual practice
was 2min of a PCP’s time to ask initial screening ques-
tions, plus a whole appointment (12-min duration)
for the further assessment of those identiﬁed as having
probable depression (Curtis, 2011). This assumption
was based on clinical advice. The sensitivity and
speciﬁcity of the HADS, used in the ﬁrst stage of the
screening system to identify patients at risk of major
depression, was estimated from published data
(Walker et al. 2007). We obtained data from the screen-
ing system to estimate the proportion of patients who
complete each stage of screening and the associated
costs based on resource use data. Estimates of the inci-
dence and prevalence of major depression in people
with cancer were taken from the published literature
(NICE, 2009a; Sharpe et al. 2004).
Treatment
We derived parameter estimates (probabilities of remis-
sion and relapse, costs and HRQoL) of outcomes for
depression treatment (in usual practice and DCPC)
from an efﬁcacy trial, SMaRT Oncology-1, that com-
pared the outcomes of patients allocated to DCPC
with those allocated to usual depression treatment
(with the PCP informed of themajor depression diagno-
sis) up to 12 months (Strong et al. 2008). We sup-
plemented the trial data with data from published
literature (where possible, estimates were taken from
systematic reviews and meta-analyses). Treatment
costs included all PCP and cancer clinic visits along
with in-patient stays and out-patient appointments
(medical and psychiatric). Costs were based on resource
use measured in SMaRT Oncology-1 and valued using
national unit costs (BMA/RPS, 2010; Curtis, 2011;
Department of Health, 2011a). Where appropriate, unit
costs included estimates for overheads and indirect
time, such as training and administration. The costs of
speciﬁc anti-cancer treatments (e.g. radiotherapy and
chemotherapy) were excluded as we assumed these
would be unchanged by depression management. The
probability of relapse was assumed to be the same
regardless of which treatment was received, based on
SMaRT Oncology-1 data (Strong et al. 2008). Estimates
of mortality rates were obtained from UK gender- and
age-speciﬁc cancer survival rates (Walters et al. 2010).
Patients with unidentiﬁed depression were assumed
not to have received treatment. The outcomes for these
patients were estimated by combining the outcomes
observed in the ‘usual care’ arm of SMaRT
Oncology-1 with a meta-analysis that compared
depression outcomes for those receiving antidepress-
ant drug treatment with those receiving no treatment
(Strong et al. 2008; Arroll et al. 2009). We estimated
the costs associated with no treatment from the health-
care resource use recorded in the ‘usual care’ arm of
SMaRT Oncology-1, minus depression-speciﬁc treat-
ment costs (Strong et al. 2008).
Analysis
Base-case analysis
Although patients attend cancer clinics at varying
intervals, it was assumed that they were formally
screened for depression in the clinic only once a year.
This assumption was based on expert advice of the
logistical arrangements and the acceptability of screen-
ing. We used a time horizon of 5 years, chosen because
this is the usual time after which patients successfully
treated would be considered ‘cured’ and would no
longer be followed up by cancer services (Parkin
et al. 2001). The base case considered the case of a
63-year-old woman, reﬂecting the mean age of patients
attending the depression screening service.
Sensitivity and scenario analysis
To reﬂect uncertainty in the inputs to the model,
we conducted probabilistic sensitivity analysis,
where distributions are placed on uncertain param-
eters. This analysis generates the probability of the
alternative options being cost-effective for a given cost-
effectiveness threshold. To reﬂect uncertainty in mod-
elling assumptions, we also considered other scenarios
including alternative assumptions about the sex and
age of the patients, the time horizon and the sensitivity
and speciﬁcity of PCP assessments. The estimate of
the incidence of depression was based on the general
population and can be considered to be conservative,
as depression incidence would be reasonably expected
to be higher in cancer patients; we therefore increased
the incidence as a scenario analysis. As our estimate of
treatment effectiveness was based on data from a
single trial, we also explored the effect of using an
alternative estimate of effectiveness derived from a
meta-analysis of systematic treatment interventions
for depression in primary care (Archer et al. 2012).
Economic analysis
We discounted both costs and outcomes at 3.5% per
annum in accordance with current UK guidance from
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the National Institute for Health and Care Excellence
(NICE, 2008). Standard decision rules were used to
identify the most cost-effective interventions in
each analysis. Speciﬁcally, we calculated incremental
cost-effectiveness ratios (ICERs), which express the
additional cost per QALY gained from an intervention
compared to the next most effective. We then applied
the current range of the UK NICE cost-effectiveness
threshold (£20000–£30000 per QALY) and deﬁned the
cost-effective intervention as the most effective option
with an ICER below this threshold (NICE, 2008).
Results
Tables 1 and 2 show the key parameters and the results
of modelling. In the base-case analysis, the addition
of systematic depression identiﬁcation and treatment
generated more QALYs than usual practice alone
(3.094 v. 3.085) but at an additional cost (£464 v.
£365). This resulted in an ICER of £11765 per QALY
gained. The probability of systematic depression
management being cost-effective at a threshold of
£20000 per QALY was more than 99%.
The results were consistent across sex and age; the
ICER for a 63-year-old man was £13418 per QALY
gained whereas the ICERs for a 50-year-old woman
and a 70-year-old woman were £11502 and £11794
per QALY gained respectively.
Varying the estimated incidence of major depression
had little effect on cost-effectiveness; doubling the inci-
dence to 4.2% only slightly reduced the ICER to £11278
per QALY gained.
Changing the time horizon from 5 to 10 and
20 years, by which time the majority of patients
would be expected to have died, resulted in ICERs of
£12443 and £8871 per QALY respectively. The prob-
ability of systematic management being cost-effective
remained in excess of 99%, regardless of the time hor-
izon considered.
In the scenario analysis we considered what the
sensitivity and speciﬁcity of usual depression identiﬁ-
cation by PCPs would have to be for the addition
Table 2. Results
Costs (£) QALYs
ICER
(£ per
QALY)
Probability that
intervention is cost-
effective at £20000
per QALY threshold
Probability that
intervention is cost-
effective at £30000
per QALY threshold
Base-case analysis (63-year-old woman, 5-year time horizon)
Usual depression management 365.27 3.085325939 0.002 0
Systematic depression management 463.61 3.093685167 11765.40 0.998 1
Scenario analyses
Sex (63-year-old man, 5-year time horizon)
Usual depression management 345.56 3.04905031 0 0
Systematic depression management 455.58 3.057249932 13417.98 1 1
Age (50-year-old woman, 5-year time horizon)
Usual depression management 383.78 3.213711974 0.001 0
Systematic depression management 483.53 3.222384569 11501.80 0.999 1
Age (70-year-old woman, 5-year time horizon)
Usual depression management 331.32 2.646375575 0.007 0
Systematic depression management 408.48 2.652918322 11794.33 0.993 1
Depression incidence (63-year-old woman, 5-year time horizon, depression incidence doubled)
Usual depression management 415.69 3.052309702 0.002 0
Systematic depression management 535.98 3.062975677 11277.82 0.998 1
Time horizon (63-year-old woman, 10-year time horizon)
Usual depression management 576.93 4.515698765 0.001 0
Systematic depression management 732.32 4.52818723 12442.67 0.999 1
Time horizon (63-year-old woman, 20-year time horizon)
Usual depression management 755.46 5.076232082 0.001 0
Systematic depression management 906.54 5.093261838 8871.31 0.999 1
Treatment effectiveness (63-year-old woman, 5-year time horizon, treatment effectiveness estimate from meta-analysis
of primary care collaborative care trials)
Usual depression management 424.10 2.987777361 0.001 0
Systematic depression management 556.32 3.000314444 10546.20 0.999 1
QALY, Quality-adjusted life year; ICER, incremental cost-effectiveness ratio.
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of systematic identiﬁcation not to be cost-effective.
We found that even if the estimated sensitivity and
speciﬁcity of usual identiﬁcation were increased to an
improbable 100%, usual practice was still not cost-
effective at commonly accepted thresholds. In this
scenario all patients with depression will be identiﬁed
in both arms and the result shows that DCPC is
more effective and cost-effective than usual depression
treatment.
Using the estimate of treatment effectiveness
from other trials of collaborative care treatment of
depression in primary care did not signiﬁcantly change
the results and generated an ICER of £10546 per
QALY.
Discussion
We found that a combined systematic approach to
the identiﬁcation and treatment of co-morbid major
depression that is integrated with cancer care is likely
to be cost-effective, when compared with usual prac-
tice. This ﬁnding was robust to variation in key
parameters.
As far as we are aware, the analysis presented here
is the ﬁrst to adequately address the cost-effectiveness
of a depression management system combining inte-
grated case identiﬁcation and treatment for major
depression co-morbid with a medical condition. Few
previous studies of the systematic identiﬁcation of
co-morbid depression have used methods appropriate
to inform resource allocation decisions (Pignone et al.
2002). Those that have used QALYs suggest that sys-
tematic screening for depression, without systematic
treatment, is not cost-effective (Paulden et al. 2009;
Valenstein et al. 2001).
Previous evaluations of the cost-effectiveness of
systematic treatment of co-morbid depression have
reported improved outcomes with increased costs in
cancer patients and patients with other chronic con-
ditions (Strong et al. 2008; NICE, 2009b), and improved
outcomes with reduced overall costs for depression
co-morbid with several other medical conditions
(Simon et al. 2007; Katon et al. 2012; Ladapo et al. 2012).
One of these studies also included a simple estimate of
screening costs (Simon et al. 2007). The results of our
study show that a more systematic and structured
approach to identiﬁcation should bemore explicitly con-
sidered in future evaluations and service developments.
This study has both strengths and limitations. Its
strengths are: the use of estimates based on the best
available data from clinical trials, other published
data and real clinical services; the use of conservative
assumptions (that is, in favour of usual practice);
and the use of sensitivity analyses to address areas
of uncertainty. There are some limitations: ﬁrst, the
estimate of sensitivity and speciﬁcity of depression
identiﬁcation by PCPs was taken from a systematic
review that included studies from several countries.
However, when the sensitivity and speciﬁcity par-
ameters for usual practice were increased to 100% in
a scenario analysis, systematic depression manage-
ment was still cost-effective. Second, there is little
evidence to inform our estimate of the incidence of
depression in cancer patients; we therefore used the
general population incidence rate of 2.1% (NICE,
2009a). As the incidence in cancer patients is likely to
be higher than this, we also determined the effect of
a rate twice that of the general population and found
that it enhanced, rather than lessened, the case for sys-
tematic management. Third, our analysis was simplis-
tic in assuming that screening is simply conducted
annually; it did not consider when screening should
best be conducted in relation to clinical events such
as diagnosis and relapse and more work is needed
to assess the best times to screen individuals for
depression. Fourth, estimates of the relative effective-
ness of usual and systematic treatment of major
depression were taken from a clinical trial that may
not necessarily generalize to routine care. The outcome
of depression with usual treatment taken from the trial
may be superior to that achieved in practice because
patients in the trial were told of their diagnosis of
depression and encouraged to see their doctors for
treatment. However, if that was the case it would
only make our estimates of the relative effectiveness
of DCPC more conservative. Fifth, not all parameters
in the model were estimated from exhaustive systema-
tic reviews. However, those parameters to which
cost-effectiveness is particularly sensitive were either
identiﬁed using such methods, or subject to extensive
scenario analysis. Sixth, the analysis only applies to
patients attending specialized cancer clinics. We
acknowledge that some people with cancer will not
attend such clinics and the results may not apply to
non-ambulant populations. Finally, the model assumes
that depression does not have an effect on mortality.
There is some evidence that depression may inﬂuence
life expectancy in cancer patients, possibly by inﬂuen-
cing adherence to cancer treatment (Katon &
Ciechanowski, 2002; Pinquart & Duberstein, 2010).
However, our assumption of no effect is conservative
with respect to the cost-effectiveness of systematic
management and relaxing it would be unlikely to
change our conclusions.
We have studied depression management in
adult patients with good prognosis cancers attending
specialist cancer out-patient clinics. The ﬁndings may
generalize to younger cancer patients and also to
those near the end of their life. Similarly, this may
have important implications for the management
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of depression co-morbid with other chronic medical
conditions in which systematic collaborative care treat-
ment has already been found to be both effective and
cost-effective (Simon et al. 2007; Katon et al. 2012;
Ladapo et al. 2012). However, in both cases further
research is needed to determine if this is the case.
Although randomized controlled trials of the whole
process of systematic identiﬁcation and treatment
would be informative, the cost and difﬁculty of orga-
nizing such trials may be prohibitive. Research, there-
fore, may most suitably take the form of clinical trials
to inform the effectiveness and cost-effectiveness of
systematic treatment for co-morbid depression, and
other types of study design to generate evidence on
the systematic identiﬁcation component (e.g. diagnos-
tic accuracy studies to generate evidence on sensitivity
and speciﬁcity and costs of identiﬁcation processes).
These data could then be combined by modelling
so as to fully consider the effectiveness and cost-
effectiveness of a systematic approach to the manage-
ment of co-morbid depression.
Conclusions
Health systems should consider the implications of
our ﬁndings when deciding on the balance of services
they commission for cancer patients. Although there
is an inevitable focus on surgical, radiological and
pharmaceutical interventions to improve cancer prog-
nosis, the cost of generating health improvement
through a systematic approach to both identifying
and treating patients with co-morbid major depression
is likely to be appreciably lower than that associated
with some of these treatments. We have studied
depression management in patients with cancer. It is
reasonable to hypothesize that our ﬁndings may
apply to other chronic medical conditions, although
further research is required to test this.
The most cost-effective precise speciﬁcation of
the systematic management system may depend on
local circumstances. Some of the parameters could be
varied, including frequency of screening and the num-
ber and content of treatment sessions.
We conclude that combining the systematic identiﬁ-
cation of major depression with systematic integrated
collaborative care treatment is cost-effective. The com-
bined uncertainty in the available evidence results in a
very small probability that this conclusion is not valid
at the cost-effectiveness thresholds used by NICE.
More work is required to determine the optimal spe-
ciﬁcations of this service, including the frequency of
screening, choice of screening instrument and cut-off
score, the intensity and duration of depression treat-
ment and the extent to which this approach is also cost-
effective for patients with major depression co-morbid
with other chronic diseases.
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